Product image of Milligest (Ethinylestradiol, Gestodene) supplied by GNH India

Milligest

Active Ingredient:
Ethinylestradiol, Gestodene
Origin:
EU

Milligest (Ethinylestradiol, Gestodene)

Ethinylestradiol and Gestodene, the active ingredients in Milligest, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and altering the endometrium.

GNH India supplies Milligest as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Milligest is a combined hormonal contraceptive that acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy.

  • Contraception: Prevents pregnancy by suppressing ovulation and altering cervical mucus.
  • Menstrual cycle regulation: Provides more predictable menstrual bleeding patterns.
  • Acne improvement: May reduce acne associated with androgen excess.

How It Works

  • Ethinylestradiol provides estrogenic activity while gestodene supplies progestogenic activity. Together they suppress the hypothalamic‑pituitary‑ovarian axis, reducing luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) secretion, which inhibits follicular development and ovulation. The progestogen also thickens cervical mucus and induces endometrial changes that are unfavorable for implantation.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Breast tenderness: discomfort or swelling of the breasts.
  • Headache: transient cranial pain.
  • Weight gain: modest increase in body weight.
  • Mood changes: irritability or emotional fluctuations.
  • Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects

  • Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
  • Arterial thrombosis: stroke or myocardial infarction.
  • Hypertension: new or worsening high blood pressure.
  • Liver dysfunction: jaundice or hepatic enzyme elevation.
  • Gallbladder disease: cholelithiasis or biliary colic.
  • Severe allergic reaction: anaphylaxis or angioedema.

Precautions & Warnings

Before initiating Milligest, consider the following precautions.

  • Assess thromboembolic risk: evaluate personal and family history of clotting disorders.
  • Avoid smoking: especially in women over 35 years of age.
  • Monitor blood pressure: check regularly for hypertension.
  • Review hepatic function: contraindicated in severe liver disease.
  • Check medication history: avoid concomitant use with strong enzyme inducers.
  • Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Avoid Interactions

Milligest may interact with several medicines.

Major Interactions (Avoid)

  • Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): reduce contraceptive efficacy.
  • Rifampicin or griseofulvin: may decrease hormonal levels.
  • Protease inhibitors (e.g., ritonavir): increase risk of adverse effects.
  • St. John’s wort: may lower contraceptive effectiveness.

Moderate Interactions (Monitor Closely)

  • Azole antifungals (e.g., ketoconazole): may raise hormone concentrations.
  • SSRIs (e.g., fluoxetine): could enhance mood‑related side effects.
  • Diuretics: may affect fluid balance and blood pressure.

Frequently Asked Questions

Milligest is a combined oral contraceptive containing ethinylestradiol and gestodene. It is primarily prescribed to prevent pregnancy in women of reproductive age. In addition to contraception, it may help regulate menstrual cycles and can be used to treat acne associated with hormonal imbalance.

The estrogen component (ethinylestradiol) and the progestogen (gestodene) work together to suppress the hypothalamic‑pituitary‑ovarian axis, lowering LH and FSH release. This prevents follicle development and ovulation. The progestogen also thickens cervical mucus and alters the endometrium, creating an environment unsuitable for implantation.

The specific dosing regimen for Milligest is determined by the prescribing healthcare professional. Typically, the medication is taken as one tablet daily, at the same time each day, but the exact schedule and any missed‑dose instructions are provided by the prescriber.

Milligest is not intended for use during pregnancy and should be discontinued if pregnancy occurs. Its safety during breastfeeding has not been fully established; women who are breastfeeding should discuss alternative contraceptive options with their healthcare provider.

To request Milligest, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any required import documentation.

Milligest contains gestodene, a third‑generation progestogen, which offers a slightly lower androgenic profile compared with older agents like levonorgestrel. Efficacy in preventing pregnancy is comparable across combined oral contraceptives, while side‑effect profiles may differ, with gestodene often associated with less acne and weight gain.

Store Milligest at ambient temperature, preferably below 25 °C. Keep the tablets in their original blister pack, away from moisture and direct sunlight. Do not refrigerate or freeze the product, and ensure the container is tightly closed to maintain stability.

Milligest is taken orally as a tablet once daily, preferably at the same time each day. It can be taken with or without food. Consistent daily intake is essential for maintaining contraceptive effectiveness.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or myocardial infarction), and severe hypertension. Women with a history of clotting disorders, certain cancers, or uncontrolled hypertension should be especially cautious.

Milligest is contraindicated in women with a known history of thromboembolic disease, estrogen‑dependent tumors, active liver disease, uncontrolled hypertension, or who are smokers over 35 years of age. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Gestodene

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT